Print
In an era of progress, one of the next goal posts is successful development of trispecifics.
Measles cases are the highest in 33 years, with more than 1,000 cases reported in 2025 as of July.
From Buffalo to the Manhattan borough, Dr. Rampal shares his journey to becoming a hematologist-oncologist.
Michael Styler, MD, received the NCCN 2025 Outstanding Contributor Award for his commitment to improving cancer care.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
As director of the FDA’s CBER, Dr. Prasad oversaw the regulation of biological products for human use.
Dr. Swoboda discusses his role as clinical investigator of the QuANTUM-Wild study, how AI can transform oncology, and more.
Oncologists share insight about the types of Hospital-Community Practice partnerships and the benefits and drawbacks to each.
The award recognizes achievements in the field of gene and cell therapies, cellular engineering, and related disciplines.
Hematology/oncology fellow Joseph Van Galen, MD, is investigating the mechanisms behind immune-related adverse events.
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
The advent of AI technologies such as machine learning has opened new avenues for predicting adverse drug reactions.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Dr. Rogers shares her career trajectory, what being a doctor is about, and a glimpse of her pet guinea pigs, Maple and Brady.
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
Experts discuss the link between dietary patterns and blood cancer risk and the shortcomings of epidemiological studies.
Dr. Locke is a lead investigator of the ZUMA-1 and ZUMA-7 trials, which led to the FDA approval of axi-cel.
The awards recognize early-, mid-, or senior-career experts who display excellence in the field.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.